- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
beta-amyloid 42 (Aβ42) antibody and antigen (Recombinant protein)
Diagnostic beta-amyloid 42 (Aβ42) antibodies (anti-beta-amyloid 42, anti-Aβ42) and antigens (recombinant beta-amyloid 42 (Aβ42) protein) for Neurodegenerative diseases Aβ42 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Go to Neurodegenerative diseases diagnostics products collection
>>
Product information
| Catalog No. | Description | US $ Price (per mg) |
|---|---|---|
| GMP-h-Aβ42-Ag01 | Beta-amyloid 42 (Aβ42) antigen | $3090.00 |
| GMP-h-Aβ42-Ab01 | Anti-human Aβ42 mouse monoclonal antibody (mAb) | $1953.00 |
| GMP-h-Aβ42-Ab02 | Anti-human Aβ42 mouse monoclonal antibody (mAb) | $1953.00 |
| GMP-h-Aβ42-Ab03 | Anti-human Aβ42 human monoclonal antibody (mAb) | $1953.00 |
| GMP-h-Aβ42-Ab04 | Anti-human Aβ42 human monoclonal antibody (mAb) | $1953.00 |
Size： 1mg | 10mg | 100mg
Product Description
| Cat No. of Pruducts | GMP-h-Aβ42-Ag01 |
| Product Name | Beta-amyloid 42 (Aβ42) antigen |
| Target/Biomarker | beta-amyloid 42 (Aβ42) |
| Alias of Target/Biomarker | AAA, ABETA, ABPP, AD1I, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4, APP |
| Expression platform | synthesized |
| Isotypes | NA |
| Bioactivity validation | beta-amyloid 42 (Aβ42) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation |
| Products description | Beta-amyloid 42 (Aβ42) antigen is synthesized |
| Purity | Purity: ≥95% (HPLC) |
| Application | positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
| Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
| Cat No. of Pruducts | GMP-h-Aβ42-Ab01,GMP-h-Aβ42-Ab02 |
| Product Name | Anti-human Aβ42 mouse monoclonal antibody (mAb) |
| Target/Biomarker | beta-amyloid 42 (Aβ42) |
| Alias of Target/Biomarker | AAA, ABETA, ABPP, AD1I, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4, APP |
| Expression platform | CHO |
| Isotypes | Mouse IgG |
| Bioactivity validation | Human beta-amyloid 42 (Aβ42) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other beta-amyloid 42 (Aβ42) antibodies in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation. |
| Tag | mFc |
| Products description | Anti-human Aβ42 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other beta-amyloid 42 (Aβ42) antibodies. |
| Reconized/Reactive Species | Human |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT. |
| Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
| Cat No. of Pruducts | GMP-h-Aβ42-Ab03,GMP-h-Aβ42-Ab04 |
| Product Name | Anti-human Aβ42 human monoclonal antibody (mAb) |
| Target/Biomarker | beta-amyloid 42 (Aβ42) |
| Alias of Target/Biomarker | AAA, ABETA, ABPP, AD1I, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4, APP |
| Expression platform | CHO |
| Isotypes | Human lgG1 |
| Bioactivity validation | Human beta-amyloid 42 (Aβ42) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other beta-amyloid 42 (Aβ42) antibodies in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation. |
| Tag | hFc |
| Products description | Anti-human Aβ42 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
| Reconized/Reactive Species | Human |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT. |
| Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Validation of GeneMedi's Aβ40/Aβ42 antibodys
The high-performance Aβ40 and Aβ42 antibody raw materials developed by GeneMedi have the advantages of good specificity and high sensitivity, and are the preferred raw materials for the development of in vitro diagnostic reagents for Alzheimer's disease.
Figure1. Indirect ELISA analysis of clone [B], [A] and [A] antibody specificity, [B] and [A] can Recognizes Aβ40, while [A] has no cross-reactivity with Aβ40 Picture indirect ELISA analysis of cloned [B], [A] and [A] antibody specificity. [B] and [A] can recognize Aβ42 , while [A] has no cross-reaction with Aβ42.
A: GMP-h-Aβ42-Ab01
B: GMP-h-Aβ42-Ab02
Sensitivity verification data
Figure2. Beta-amyloid(1-42) antibodies (GMP-h-Aβ42-Ab02 and GMP-h-Aβ42-Ab01) established a standard curve by chemiluminescence method, and the detection range of Aβ42 was 100-1700 pg/mL.
Understanding Beta Amyloid
The 2023 Alzheimer's Association International Conference (AAIC) released a draft proposal for
AD diagnostic standards, which introduces blood-based biomarker testing for the first time. AD
can be diagnosed through plasma markers such as Aβ42, Aβ40, P-tau181, P-tau217, P-tau231, NFL,
GFAP (as shown in the table above). These markers have not yet been subjected to large-scale
clinical studies, and relevant groups need to be Do further analysis. For the diagnosis of AD,
it is necessary to rely on comprehensive methods such as clinical manifestations and imaging.
Aβ40 polypeptide and Aβ42 polypeptide are common forms found in human cerebrospinal fluid and
serum. It is generally believed that Aβ42 peptide has stronger neurotoxicity and is more prone
to aggregation. Changes in Aβ42 peptide concentration in human cerebrospinal fluid and blood are
associated with Alzheimer's disease.
Beta Amyloid is produced by the hydrolysis of amyloid precursor protein (APP) by β and γ secretases and is
composed of 38-43 amino acids with toxic effects (as shown on the right ).
Eli Lilly's new drug Donanemab is an investigational drug for the treatment of AD. It is a specific antibody targeting the N-terminal pyroglutamate Aβ epitope of amyloid plaques. Donanemab antibody can significantly reduce blood pTau217 levels. A significant decrease in plasma pTau217 levels was observed after 12 weeks of treatment with donanemab compared with placebo and was sustained throughout the 76 weeks of the study. Mean plasma pTau217 levels in the donanemab treatment group decreased by 23% from baseline. In contrast, mean plasma pTau217 levels in the placebo group continued to increase by 6% from baseline to the end of the study, as shown below [7]. pTau217 may become a companion diagnostic indicator in the treatment of AD by Donanemab
Click to get more Data / Case study about the product.
Target/Biomarker information
Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. Low plasma Aβ42/40 was associated with more pronounced decline in cognitive function (measured by multiple outcomes) over time. Findings suggest that plasma Aβ42/40 may be used to identify people at risk of cognitive decline, being an alternative to more complex and expensive measures, such as positron emission tomography imaging or cerebrospinal fluid measurement.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Facebook
LinkedIn
Twitter
Comments
No comments yet.